Short answer
Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
Beta Bionics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the detailed results
- Results announcement dated July 29, 2026, giving investors the company’s latest operating update
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $32.0M, up 38%, led by PBP sales of $11.6M, up 153%, while DME grew 9% to $20.4M
- Gross margin improved to 59.0% from 53.8%, supporting unchanged full-year revenue guidance of $131M to $136M
- Operating loss widened to $25.6M and net loss to $23.4M, highlighting continued substantial cash burn despite stronger sales
- Cash, equivalents and investments totaled $225.2M at June 30, 2026, providing funding for commercialization and clinical development
- Type 2 diabetes pivotal trial enrollment began, while Mint commercialization moved to end-Q2 2027, both dependent on FDA clearance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beta Bionics, Inc. 8-K filings
Get the next BBNX 8-K as it lands
Follow BBNX for push alerts, or ask the research agent what this filing means.